The conference will feature distinguished speakers covering a broad spectrum of topics ranging from basic science to clinical therapeutics. Presenters and discussants will explore current issues and debate controversial topics. Case presentations will be given by the faculty and the audience will participate by an interactive audience response system to stimulate discussion on diagnosis and management. This program should be of interest to professionals actively engaged clinically or scientifically in all facets of GI cancer research and care, including oncologists, surgeons, radiologists, general scientists, fellows, young investigators, nurses and pharmacists.
After attending this activity, the participant will demonstrate the ability to:
bIdentify recent advances and innovations in the treatment of GI malignancies within the past 12 months
bDescribe emerging evidence from current clinical trials that may impact treatment decision making in GI oncology
bFormulate a multi-modal approach to the treatment of GI cancers including Gastric, HCC, Cholangiocarcinoma, Pancreatic and Colorectal Cancers
bAnalyze how recent clinical trial data demonstrate a significant survival benefit with a combination chemotherapy regimen in patients with metastatic pancreatic cancer
bAssess how new developments in treating advanced pancreas adenocarcinoma may help guide post surgical treatment strategies
bDefine which patients will benefit from sequencing strategies of anti-EGFR and anti-VEGF therapies, for all patients with normal KRAS, regardless of BRAF status (based on 2 large prospective randomized trial)
bDiscuss the multi-center trial results that demonstrate that sunitinib, a multi-targeted TKI may delay disease progression in patients with pancreatic neuroendocrine tumors and contribute to increased survival
bUtilize the prognostic value of 8 molecular markers on relapse-free survival and stages II and III colon cancer.
bDefine the benefit for specific subgroups of stage III colon cancer with only 3 months of adjuvant chemotherapy (rather than the standard 6 months).